The "Holy Grail" of DME Treatment?

Riad Sherif, CEO of Oculis, discusses innovative treatments targeting diabetic macular edema (DME) and acute optic neuritis (AON) – OCS-01 and OCS-05. Leveraging OPTIREACH® technology, OCS-01 allows topical delivery of dexamethasone eye drops, potentially transforming DME management by enhancing accessibility and patient compliance. Early treatment can significantly improve prognosis in DME patients. OCS-05 shows promise for neuroprotection in AON and is moving towards FDA reviews, demonstrating significant advancements in retinal and neuro-ophthalmic therapies.

About the Author(s)

Alun Evans

More Articles by Alun Evans